IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
NEW YORK, Nov. 28, 2012 /PRNewswire/ — IntelliCell BioSciences, Inc. (“Company”) (OTCQB: SVFC) announced today that it has entered a sponsored research agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey.
Under terms of the agreement, the New Jersey Center for Biomaterials will be conducting a series of research projects that will further define the unique characteristics and properties of IntelliCell’s proprietary cellular population. The work will be conducted on behalf of IntelliCell under the direction of Professor Joachim Kohn, the noted researcher and inventor who directs the New Jersey Center for Biomaterials.
Initial research will focus on documenting any differences between IntelliCell’s proprietary cellular population and similar cell populations isolated from human adipose tissue using conventional methods of cell isolation. After successful completion of the initial phases of the clinical research, the Company hopes to engage the New Jersey Center for Biomaterials in development projects that may lead to bioengineered products containing the proprietary IntelliCell cellular population and products under development at the New Jersey Center for Biomaterials.
Dr. Steven Victor, Chairman and CEO of IntelliCell stated, “We are very pleased to be working with Professor Kohn and the New Jersey Center for Biomaterials. Our vision for the future includes a number of bio-applications whereby we can apply our technology to exciting new areas in regenerative medicine and work with top tier research institutions in the United States.”
Professor Joachim Kohn, Director of the New Jersey Center for Biomaterials at Rutgers,-The State University of New Jersey added, “This is a truly exciting opportunity for us. We have a number of highly advanced scaffolds for regenerative therapies (e.g. re-growing bone, nerve, and skin), and we expect that IntelliCell’s cell populations will significantly enhance the effectiveness of our biomaterials-based scaffolds. In this collaborative research project, we are combining the outstanding cell biology expertise of IntelliCell with the expertise of our chemists and materials scientists. We believe that through this collaboration, we will be able to demonstrate the merits of interdisciplinary research efforts between industry and academia. In addition, emerging companies like IntelliCell are the main driving force for health care innovation, and we are delighted to assist such companies with technologies under development.”
Added Robert Sexauer, EVP of Clinical Development at IntelliCell; “We are looking forward to working with Professor Kohn and his team in our primary focus of translating IntelliCell technology into clinical opportunities.”
About IntelliCell BioSciences
IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative and preventative conditions of disease states with high unmet clinical needs. The Company has several patent-pending applications including an industry unique method of obtaining autologous stromal vascular fraction cells (SVF) from the vasculature surrounding adipose tissue containing adult stem cells and a robust population of regenerative healing cells. The Company is also pioneering the development of autologous and allogeneic cells from living and non-living tissue donors for research purposes. IntelliCell is planning a series of in-human clinical studies with top tier universities for the treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics. The Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into its ambulatory surgery center.
About Rutgers-The State University of New Jersey and the New Jersey Center for Biomaterials
The New Jersey Center for Biomaterials, based at Rutgers -The State University of New Jersey, is one of the leading academic research Centers to address the challenges of biomaterials discovery and optimization through a rational interdisciplinary approach. This approach includes expertise in polymer chemistry, materials science, cell and stem cell biology, and prototype development. Since 1997, the Center has been a nationally recognized resource in biomaterials science with a major emphasis on industrial interactions. The Center’s scientific strengths lie in the design, synthesis, characterization and fabrication of new materials for tissue engineering, drug delivery and regenerative medicine. The Center manages sponsored programs of inventive research, postdoctoral education and translational research leading to partnerships with industry. These activities synergize to provide an enriched environment for innovative research that focuses on the ultimate societal goals of improved healthcare and quality of life.
About Professor Joachim Kohn
Joachim Kohn received a PhD from the Weizmann Institute of Science and trained as a postdoctoral scientist under Professor Robert Langer at the Massachusetts Institute of Technology. He is currently Director of the New Jersey Center for Biomaterials and Board of Governors Professor of Chemistry at Rutgers University. His research focuses on the development of biomaterials for specific medical applications. Kohn has developed a new “discovery paradigm” for biomaterials using combinatorial and computational methods to optimize the interaction of cells and stem cells with biomaterials. His work resulted in the discovery of optimized biomaterials for coronary vessel stenting, hard tissue regeneration, and drug delivery. Currently, four companies develop medical products based on Kohn’s technologies and, to-date, about 30,000 patients benefit from these products.
Certain statements set forth in this press release constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will likely,” “should,” “could,” “would,” “may” or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.
IntelliCell BioSciences, Inc.
Email Contact: Ametelitsa@intellicellbiosciences.com
SOURCE IntelliCell BioSciences, Inc.